SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting

NCT ID: NCT02701439

Last Updated: 2016-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1050 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is investigating a better method to see if someone has tuberculosis (TB) as compared to the method that is being used now.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TB is a disease caused by a bacterium called Mycobacterium tuberculosis that can affect the lungs or other parts of the body. In most of the world and in Mbarara, Uganda, the method of diagnosis that is used is AFB smear microscopy. This method is widely available, inexpensive and rapid. However, this method's ability to truly detect people having TB is poor. That is, if someone has TB, the test results may say that they are negative, leading to delays in diagnosis, disease progression, and an ongoing transmission of the bacteria.

The new test for TB diagnosis we are studying is called the Small Membrane Filtration (SMF) method. This test that is being compared to the method currently being used and is very similar to the one that is currently used (standard smear microscopy) but has the advantage of concentrating the sputum (mucus) so that we can more easily see if bacteria are present in the sputum. It is hoped that a better way of knowing if someone has TB will help doctors decide when people need to be treated for TB and when not, which will improve the health of patients and help avoid passing the infection to others.

This study will enroll 740 HIV-infected and 310 HIV-uninfected adults with culture confirmed pulmonary TB. These individuals will be identified prospectively at two TB clinics in Mbarara, Uganda.

Study hypothesis: The investigators will assume that one sputum sample will be equivalent to two (null hypothesis) with respect to sensitivity unless we have evidence that the use of two has higher sensitivity (alternative hypothesis). The investigators will assume that SMF is equivalent to AFB smear with respect to sensitivity and specificity unless the investigators find evidence it is superior. The investigators will assume that SMF is equivalent to Xpert unless the investigators find evidence that Xpert is superior.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-infected

Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.

Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:

* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention

Small membrane filtration

Intervention Type DEVICE

Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:

* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention will be administered to both arms

HIV negative

Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.

Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:

* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention

Small membrane filtration

Intervention Type DEVICE

Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:

* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention will be administered to both arms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Small membrane filtration

Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:

* Abbreviated demographic and clinical evaluation
* TB history and evaluation
* Obtain three sputum samples - one early morning sample and two spot samples
* HIV testing (and CD4 if positive)
* Chest radiograph
* Small membrane filtration intervention will be administered to both arms

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (≥18 years)
* Pulmonary TB suspect defined as any person who presents with a productive cough for more than 2 weeks AND accompanied by at least one other respiratory symptom (shortness of breath, chest pains, hemoptysis) and/or constitutional symptom (loss of appetite, weight loss, fever, night sweats, and fatigue) (6).
* Willing to undergo TB evaluation and spontaneously expectorate ≥2 mL of sputum
* Willing to be tested for HIV, if no results available within past 6 months

Exclusion Criteria

* Too ill or unable to provide written consent
* Treated with TB drugs for more than 3 days
* Extra-pulmonary or disseminated TB without pulmonary involvement (i.e. no cough)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston University

OTHER

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role collaborator

Epicentre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yap Boum II, PhD

Role: PRINCIPAL_INVESTIGATOR

Epicentre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Epicentre Mbarara Research Base

Mbarara, Mbarara, Uganda

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Uganda

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SMF-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TB Screening Improves Preventive Therapy Uptake
NCT04557176 ACTIVE_NOT_RECRUITING NA